ESSA Pharma to Participate in Three Upcoming Investor Conferences
Get Alerts EPIX Hot Sheet
Join SI Premium – FREE
VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings at three upcoming virtual investor conferences. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
Presentation Details
Event: Jefferies London Healthcare ConferenceFormat (on-demand): Fireside ChatDate: Thursday, November 18, 2021Time: 8:00 a.m. GMT / 3:00 a.m. ET
Event: Piper Sandler 33rd Annual Healthcare Conference Format (on-demand): Fireside ChatDate: Monday, November 22, 2021Time: 10 a.m. ET
Event: Evercore ISI 4th Annual HealthCONx Virtual Conference Format (on-demand): Fireside Chat Date: Thursday, December 2, 2021Time: 1:50 p.m. ET
Webcasts of the events can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the events, the webcasts will be archived on the ESSA website for 90 days.
About ESSA Pharma Inc.ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-participate-in-three-upcoming-investor-conferences-301418273.html
SOURCE ESSA Pharma Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Borussia Dortmund GmbH & Co. KGaA: Borussia Dortmund publishes preliminary figures for the 2025/2026 financial year
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
- Meridian Announces Application for Admission of Shares
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share